Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic

  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roivant Sciences Ltd (NQ: ROIV )

12.70 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roivant Sciences Ltd

< Previous 1 2 3 4 5 6 7 8 Next >
Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
3 Biotech Stocks That Analysts Are Drooling Over
With the medical science realm representing one of the most complex markets, these top analyst biotech picks can be worth your time. 
Via InvestorPlace
Roivant to Report Financial Results for the Quarter Ended June 30, 2023, and Provide Business Update on Monday, August 14, 2023
From Roivant Sciences
Via GlobeNewswire
Roivant Announces Redemption of Outstanding Warrants
From Roivant Sciences
Via GlobeNewswire
2 Magnificient Growth Stocks I'm Buying in August
These biotech stocks could markedly outperform the broader market. 
Via The Motley Fool
Roivant Sciences's Return on Invested Capital Insights
Via Benzinga
Earnings Scheduled For August 14, 2023
Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report quarterly loss at $0.23 per share on revenue of $6.88 million. 
Via Benzinga
Analyst Expectations for Roivant Sciences's Future
Via Benzinga
Vivek 'Da Vek' Ramaswamy: The 2024 Presidential Candidate Who Might Just Rap His Inauguration Speech
Donald Trump and Ron DeSantis have been the runaway favorites for the GOP nomination in the 2024 election, but there’s one candidate that has been climbing up the polls and gaining support from... 
Via Benzinga
Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program with First Patient Dosed in Global Phase 2 Trial of Novel Anti-TL1A Antibody RVT-3101 in Crohn’s Disease
From Roivant Sciences
Via GlobeNewswire
3 Biotech Stocks for Getting Rich in 2023
These 3 biotech stocks have seen stable or growing revenue this year. This makes them companies to keep on your watchlist. 
Via InvestorPlace
2 Nasdaq Stocks That Could Soar This Week
BridgeBio Pharma and Roivant Sciences could make big moves this week. 
Via The Motley Fool
Hollywood Wants To Use AI Replicas Of Actors, Major US Banks Deliver Q2 Earnings, Artificial Sweetener Aspartame Classified As 'Possible Carcinogen:' Today's Top Stories
Benzinga 
Via Benzinga
Why Shares of Roivant Sciences Rose Wednesday
The pharmaceutical company released fourth-quarter earnings. 
Via The Motley Fool
Roivant Surges As Roche Reportedly Considers $7 Billion Drug Takeover
The report sent Roivant Sciences higher Friday, but a deal is far from guaranteed. 
Via Investor's Business Daily
Republican Presidential Candidate Vivek Ramaswamy Founded Roivant In Discussions With Roche For $7B Stomach Disease(s) Drug Deal
Roivant Sciences Ltd (NASDAQ: ROIV), a biotech company founded by Vivek Ramaswamy, a Republican presidential candidate, is reportedly in discussions with Roche Holdings AG (OTC: RHHBY) 
Via Benzinga
Roivant Ranks No. 25 on Fast Company’s Fifth Annual List of the 100 Best Workplaces for Innovators and is the Winner on the Science and Technology List as a Part of the Best Workplaces for Innovators Program
Joining Adobe, Spotify, Nvidia, Morgan Stanley, and many others 
From Roivant Sciences
Via GlobeNewswire
Schrödinger To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday
Keybanc boosted the price target for Micron Technology, Inc. (NASDAQ: MU) from $70 to $80. Keybanc analyst John Vinh maintained an Overweight rating. Micron shares rose 3.9% to $69.70 in pre-market... 
Via Benzinga
Why Roivant Sciences Stock is Trading Higher Today
Roivant Sciences Ltd (NASDAQ: ROIV) released results from the chronic period of the TUSCANY-2 Phase 2b study of RVT-3101 in adult patients with  
Via Benzinga
A First-Ever In Ulcerative Colitis Sends Roivant Stock Into A Breakout
The company is testing a treatment that blocks an inflammatory ligand in patients with ulcerative colitis. 
Via Investor's Business Daily
UPDATE -- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Nasdaq, S&P 500 Futures Slip Ahead Of Powell Speech, Bank Stress Test Results: Why This Analyst Rates Stocks 'Overweight' And Says 'Buy Weakness'
Via Benzinga
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
5 Analysts Have This to Say About Roivant Sciences
Via Benzinga
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provide Business Update on Wednesday, June 28, 2023
From Roivant Sciences
Via GlobeNewswire
Why Avid Bioservices Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) shares climbed 422% to $0.5572 after the company announced acquisition of Spyre Therapeutics and concurrent oversubscribed $210 million private... 
Via Benzinga
Why Roivant Sciences Stock Is Perking Up Today
Positive long-term data for a novel ulcerative colitis medication is fueling a double-digit rise in the drugmaker's stock. 
Via The Motley Fool
Steelcase, Commercial Metals And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded mixed, with the Dow Jones dropping around 50 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Roivant Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy from the Induction to Chronic Period
From Roivant Sciences
Via GlobeNewswire
Roivant to Host Investor Call at 8:00 AM ET on Thursday, June 22 to Review Results from the Chronic Period of TUSCANY-2, a Large Global Phase 2b Study of RVT-3101 (Anti-TL1A Antibody) in Ulcerative Colitis
From Roivant Sciences
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.